MedInCell Stock Rises 4.23% to €26.14, Breaking Technical Resistance
The biotech company from Montpellier opens the trading session on Wednesday, May 6, 2026, with a strong acceleration. The MedInCell stock climbs 4.23% to €26.14 in a well-oriented Parisian market, extending its rebound from the previous day.
The price clearly surpasses its identified resistance at €25.12, after approaching it the previous day during a session that saw the stock challenge this graphical threshold. The breakout is accompanied by an overflow of the upper boundary of the Bollinger Bands at €25.78. The price now moves above this envelope, a configuration that indicates a short-term rush. The RSI at 58 remains in the neutral zone and does not send a marked overbought signal. Over seven days, the progress reaches 14.35%. The stock also moves back above its 50-day and 200-day moving averages, located at €22.92 and €24.27 respectively.
Focus on the R&D Day on May 12
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
The financial calendar sets the next concrete appointment in less than a week, with an R&D day scheduled live on Tuesday, May 12, 2026. The annual results for the fiscal year April 2025-March 2026 will follow on Tuesday, June 16. During the semi-annual publication covering the period April-September 2025, the company mentioned an expected acceleration of revenues in the coming years with olanzapine LAI, for which the registration dossier (NDA) has been submitted. Among the opportunities mentioned was also the revision of the 2025 sales forecasts for UZEDY® by the partner Teva, now in a range of $190 to $200 million. The annual performance is nearly 70%, with the stock having doubled its low from the beginning of the year. The May 12 meeting will provide an update on the portfolio of development programs.
We are pleased with the company’s growth and momentum.
Total income €14,1 million; Revenues €11,6 million (+35 %); UZEDY® royalties €4,2 million; Operating result €(6,6) million (improved 13 % year-over-year); Net result €(16 078) thousand; Cash and low-risk financial investments €53,5 million (incl. €49,8 million cash and €3,7 million low-risk investments); Net financial debt €17 629 thousand; NDA for Olanzapine LAI submitted to FDA on December 9, 2025; AbbVie partnership advancing with regulatory package expected in 2026.
Risks mentioned
Foreign exchange risk: weakness of USD vs EUR impacted revenues and generated ~€1 million FX losses
Dependency on partner commercialization (Teva) for UZEDY® royalties and sales forecasts
Regulatory risk: approvals (e.g., Olanzapine LAI) and acceptance for review uncertain
Financial volatility linked to fair value revaluation of EIB BSA warrants (non-cash €6,8 million impact)
Opportunities identified
Olanzapine LAI: NDA submitted and potential launch could be a major growth catalyst
UZEDY®: upward revision of 2025 net sales forecast by Teva (from $160 million to $190-200 million)
AbbVie partnership: first program advancing toward first-in-human trials (regulatory package expected 2026)
Gates Foundation financing: new $3 million envelope to advance mdc-STM malaria program
Expanded geographic approvals (Canada, South Korea) supporting broader commercialization
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
